Nasdaq · CIK 0001745999
BEAM Beam Therapeutics Inc.
Insider trading from SEC Form 4. Last filing 10 d ago. Close $25.70 on Oct 9, 2026, +25% from the 52-week low and -32% from the high.
Last 90 days
Net insider value
-$4,565
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$4,565 by 1 insider
Insiders on file
14
with a Form 4 at this company
Price and insider trades, last year
BEAMOct 9, 2026 · close 25.70
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Beam Therapeutics Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 2Weak | Bethany J Cavanagh SVP, Finance and Treasurer sell | $4,565 187 shares | -0% | +18% from low-36% from high | |
| 15Weak | Giuseppe Ciaramella President sell | $1.1M 35,000 shares | -16% | +122% from low-9% from high | |
| 30Weak | John M. Evans CEO sell | $1.4M 50,000 shares | -5% | +101% from low-17% from high | |
| 16Weak | Christine Bellon Chief Legal Officer sell | $47k 1,371 shares | -1% | +136% from low-3% from high | |
| 34Weak | Bethany J Cavanagh SVP, Finance and Treasurer sell | $217k 6,198 shares | -15% | +136% from low-3% from high | |
| 26Weak | Bethany J Cavanagh SVP, Finance and Treasurer sell | $91k 3,034 shares | -7% | +113% from low-13% from high | |
| 35Weak | Christine Bellon Chief Legal Officer sell | $645k 18,629 shares | -16% | +120% from low-9% from high | |
| 9Weak | Christine Bellon Chief Legal Officer sell | $34k 1,254 shares | -1% | +91% from low-19% from high | |
| 21Weak | Sravan Kumar Emany Chief Financial Officer sell | $171k 6,294 shares | -8% | +91% from low-19% from high | |
| 32Weak | Fmr LLC owner, other sell | $12k 459 shares | -97% | +84% from low-22% from high | |
| 30Weak | John M. Evans CEO sell | $1.2M 50,000 shares | -5% | +66% from low-29% from high | |
| 10Weak | Christine Bellon Chief Legal Officer sell | $9,150 373 shares | -0% | +66% from low-29% from high | |
| 17Weak | Bethany J Cavanagh SVP, Finance and Treasurer sell | $11k 467 shares | -1% | +66% from low-29% from high | |
| 37Weak | Fmr LLC owner, other sell | $992k 48,374 shares | -2% | +39% from low-41% from high | |
| 0Weak | Amy Simon Chief Medical Officer sell | $24k 1,250 shares | -2% | +21% from low-49% from high | |
| 39Weak | Amy Simon Chief Medical Officer sell | $548k 30,563 shares | -32% | 0% from low-48% from high | |
| 24Weak | Bethany J Cavanagh SVP, Finance and Treasurer sell | $55k 3,015 shares | -6% | 0% from low-48% from high | |
| 26Weak | Giuseppe Ciaramella President sell | $136k 7,434 shares | -4% | 0% from low-48% from high | |
| 39Weak | John M. Evans CEO sell | $563k 30,663 shares | -3% | 0% from low-48% from high | |
| 20Weak | Christine Bellon Chief Legal Officer sell | $104k 5,674 shares | -5% | 0% from low-48% from high | |
| 27Weak | Bethany J Cavanagh SVP, Finance and Treasurer sell | $220k 6,287 shares | -14% | - | |
| 3Weak | Christine Bellon Chief Legal Officer sell | $340k 10,000 shares | -9% | - | |
| 27Weak | John M. Evans CEO sell | $802k 30,000 shares | -3% | - | |
| 15Weak | Bethany J Cavanagh SVP, Finance and Treasurer sell | $28k 1,117 shares | -2% | - | |
| 8Weak | Christine Bellon Chief Legal Officer sell | $31k 1,241 shares | -1% | - | |
| 35Weak | Giuseppe Ciaramella President sell | $1.3M 51,110 shares | -32% | - | |
| 15Weak | Giuseppe Ciaramella President sell | $1.3M 51,110 shares | -24% | - |
Transactions
The last 91 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Bethany J Cavanagh SVP, Finance and Treasurer | SOpen-market sale Common Stock10b5-1 | -187 | $24.41 | $4,565 | 50,984 | 10 d ago |
| Sep 24, 2026 | Giuseppe Ciaramella President | GGift Common Stock | -123,407 | $0.00 | $0 | 130,504 | 17 d ago |
| Feb 24, 2026 | Giuseppe Ciaramella President | MOption exercise Common Stock10b5-1 | +35,000 | $17.00 | $595k | 225,216 | Feb 26, 2026 |
| Feb 24, 2026 | Giuseppe Ciaramella President | SOpen-market sale Common Stock10b5-1 | -35,000 | $32.00 | $1.1M | 190,216 | Feb 26, 2026 |
| Feb 24, 2026 | Giuseppe Ciaramella President | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -35,000 | $0.00 | $0 | 397,313 | Feb 26, 2026 |
| Jan 31, 2026 | Amy Simon Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +88,500 | $0.00 | $0 | 88,500 | Feb 2, 2026 |
| Jan 31, 2026 | Christine Bellon Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Feb 2, 2026 |
| Jan 31, 2026 | Sravan Kumar Emany Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +63,500 | $0.00 | $0 | 63,500 | Feb 2, 2026 |
| Jan 31, 2026 | Bethany J Cavanagh SVP, Finance and Treasurer | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Feb 2, 2026 |
| Jan 31, 2026 | Giuseppe Ciaramella President | AGrant or award Stock Option (Right to Buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Feb 2, 2026 |
| Jan 29, 2026 | John M. Evans CEO | MOption exercise Common Stock10b5-1 | +19,336 | $0.67 | $13k | 1,006,003 | Feb 2, 2026 |
| Jan 29, 2026 | John M. Evans CEO | MOption exercise Common Stock10b5-1 | +5,664 | $0.67 | $3,795 | 1,011,667 | Feb 2, 2026 |
| Jan 29, 2026 | John M. Evans CEO | SOpen-market sale Common Stock10b5-1 | -16,333 | $29.19 | $477k | 995,334 | Feb 2, 2026 |
| Jan 29, 2026 | John M. Evans CEO | SOpen-market sale Common Stock10b5-1 | -8,667 | $29.74 | $258k | 986,667 | Feb 2, 2026 |
| Jan 30, 2026 | John M. Evans CEO | MOption exercise Common Stock10b5-1 | +25,000 | $0.67 | $17k | 1,011,667 | Feb 2, 2026 |
| Jan 30, 2026 | John M. Evans CEO | SOpen-market sale Common Stock10b5-1 | -22,094 | $28.27 | $625k | 989,573 | Feb 2, 2026 |
| Jan 30, 2026 | John M. Evans CEO | SOpen-market sale Common Stock10b5-1 | -2,906 | $29.00 | $84k | 986,667 | Feb 2, 2026 |
| Jan 29, 2026 | John M. Evans CEO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -19,336 | $0.00 | $0 | 0 | Feb 2, 2026 |
| Jan 29, 2026 | John M. Evans CEO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,664 | $0.00 | $0 | 93,672 | Feb 2, 2026 |
| Jan 30, 2026 | John M. Evans CEO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 68,672 | Feb 2, 2026 |
| Jan 31, 2026 | John M. Evans CEO | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +180,000 | $0.00 | $0 | 180,000 | Feb 2, 2026 |
| Jan 22, 2026 | Christine Bellon Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -1,371 | $34.00 | $47k | 95,667 | Jan 26, 2026 |
| Jan 22, 2026 | Bethany J Cavanagh SVP, Finance and Treasurer | SOpen-market sale Common Stock10b5-1 | -6,198 | $35.00 | $217k | 34,813 | Jan 26, 2026 |
| Jan 20, 2026 | Bethany J Cavanagh SVP, Finance and Treasurer | SOpen-market sale Common Stock10b5-1 | -3,034 | $30.12 | $91k | 41,011 | Jan 21, 2026 |
| Jan 15, 2026 | Christine Bellon Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -2,111 | $33.62 | $71k | 113,556 | Jan 20, 2026 |
| Jan 15, 2026 | Christine Bellon Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -15,959 | $34.72 | $554k | 97,597 | Jan 20, 2026 |
| Jan 15, 2026 | Christine Bellon Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -559 | $35.40 | $20k | 97,038 | Jan 20, 2026 |
| Dec 31, 2025 | Amy Simon Chief Medical Officer | AGrant or award Common Stock | +12,500 | $0.00 | $0 | 77,364 | Jan 5, 2026 |
| Dec 31, 2025 | Christine Bellon Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -1,254 | $27.10 | $34k | 115,667 | Jan 5, 2026 |
| Dec 31, 2025 | Sravan Kumar Emany Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -6,294 | $27.10 | $171k | 73,706 | Jan 5, 2026 |
| Oct 27, 2025 | Fmr LLC owner, other | SOpen-market sale Common Stockindirect: FMR Capital, Inc. | -459 | $26.68 | $12k | 14 | Oct 29, 2025 |
| Oct 6, 2025 | Fmr LLC owner, other | GGift Common Stockindirect: Shares held by persons and entities whose shares are subject to reporting by the undersigned. | -1,232,434 | $0.00 | $0 | 841,231 | Oct 8, 2025 |
| Oct 1, 2025 | John M. Evans CEO | MOption exercise Common Stock10b5-1 | +25,000 | $0.67 | $17k | 1,011,667 | Oct 3, 2025 |
| Oct 1, 2025 | Bethany J Cavanagh SVP, Finance and Treasurer | SOpen-market sale Common Stock10b5-1 | -467 | $24.53 | $11k | 44,045 | Oct 3, 2025 |
| Oct 1, 2025 | Christine Bellon Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -373 | $24.53 | $9,150 | 116,921 | Oct 3, 2025 |
| Oct 1, 2025 | John M. Evans CEO | SOpen-market sale Common Stock10b5-1 | -25,000 | $24.51 | $613k | 986,667 | Oct 3, 2025 |
| Oct 2, 2025 | John M. Evans CEO | MOption exercise Common Stock10b5-1 | +25,000 | $0.67 | $17k | 1,011,667 | Oct 3, 2025 |
| Oct 2, 2025 | John M. Evans CEO | SOpen-market sale Common Stock10b5-1 | -25,000 | $24.63 | $616k | 986,667 | Oct 3, 2025 |
| Oct 1, 2025 | John M. Evans CEO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 44,336 | Oct 3, 2025 |
| Oct 2, 2025 | John M. Evans CEO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 19,336 | Oct 3, 2025 |
| Jul 30, 2025 | Fmr LLC owner, other | SOpen-market sale Common Stockindirect: Shares held by persons and entities whose shares are subject to reporting by the undersigned. | -48,374 | $20.50 | $992k | 2,073,665 | Aug 1, 2025 |
| Jul 1, 2025 | Amy Simon Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -374 | $16.94 | $6,336 | 65,740 | Jul 3, 2025 |
| Jul 3, 2025 | Amy Simon Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -876 | $20.12 | $18k | 64,864 | Jul 3, 2025 |
| Jun 4, 2025 | Kathleen E Walsh director | AGrant or award Stock Option (Right to Buy)derivative | +33,662 | $0.00 | $0 | 33,662 | Jun 6, 2025 |
| Jun 4, 2025 | Mark Fishman director | AGrant or award Stock Option (Right to Buy)derivative | +33,662 | $0.00 | $0 | 33,662 | Jun 6, 2025 |
| Jun 4, 2025 | Chirfi Guindo director | AGrant or award Stock Option (Right to Buy)derivative | +33,662 | $0.00 | $0 | 33,662 | Jun 6, 2025 |
| Jun 4, 2025 | Christi Shaw director | AGrant or award Stock Option (Right to Buy)derivative | +33,662 | $0.00 | $0 | 33,662 | Jun 6, 2025 |
| Jun 4, 2025 | Carole Ho director | AGrant or award Stock Option (Right to Buy)derivative | +33,662 | $0.00 | $0 | 33,662 | Jun 6, 2025 |
| Jun 4, 2025 | Graham K Cooper director | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +33,662 | $0.00 | $0 | 33,662 | Jun 6, 2025 |
| Jun 4, 2025 | John Maraganore director | AGrant or award Stock Option (Right to Buy)derivative | +33,662 | $0.00 | $0 | 33,662 | Jun 6, 2025 |
| Apr 1, 2025 | Amy Simon Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -9,566 | $18.35 | $176k | 86,739 | Apr 3, 2025 |
| Apr 1, 2025 | Bethany J Cavanagh SVP, Finance and Treasurer | SOpen-market sale Common Stock10b5-1 | -3,015 | $18.35 | $55k | 44,512 | Apr 3, 2025 |
| Apr 1, 2025 | Giuseppe Ciaramella President | SOpen-market sale Common Stock10b5-1 | -7,434 | $18.35 | $136k | 190,216 | Apr 3, 2025 |
| Apr 1, 2025 | John M. Evans CEO | SOpen-market sale Common Stock10b5-1 | -30,663 | $18.35 | $563k | 986,249 | Apr 3, 2025 |
| Apr 1, 2025 | Christine Bellon Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -5,674 | $18.35 | $104k | 117,294 | Apr 3, 2025 |
| Apr 2, 2025 | Amy Simon Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -20,997 | $17.73 | $372k | 65,742 | Apr 3, 2025 |
| Mar 31, 2025 | Amy Simon Chief Medical Officer | AGrant or award Common Stock | +27,500 | $0.00 | $0 | 96,305 | Apr 2, 2025 |
| Jan 30, 2025 | John M. Evans CEO | MOption exercise Common Stock10b5-1 | +30,000 | $0.67 | $20k | 968,659 | Apr 2, 2025 |
| Mar 31, 2025 | Christine Bellon Chief Legal Officer | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 122,968 | Apr 2, 2025 |
| Mar 31, 2025 | Giuseppe Ciaramella President | AGrant or award Common Stock | +35,000 | $0.00 | $0 | 197,650 | Apr 2, 2025 |
| Mar 31, 2025 | Bethany J Cavanagh SVP, Finance and Treasurer | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 47,527 | Apr 2, 2025 |
| Mar 31, 2025 | John M. Evans CEO | AGrant or award Common Stock | +77,500 | $0.00 | $0 | 1,016,159 | Apr 2, 2025 |
| Jan 30, 2025 | John M. Evans CEO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -30,000 | $0.00 | $0 | 69,336 | Apr 2, 2025 |
| Feb 18, 2025 | Bethany J Cavanagh SVP, Finance and Treasurer | SOpen-market sale Common Stock10b5-1 | -6,287 | $35.00 | $220k | 37,527 | Feb 20, 2025 |
| Feb 14, 2025 | Christine Bellon Chief Legal Officer | MOption exercise Common Stock10b5-1 | +9,492 | $7.22 | $69k | 112,460 | Feb 19, 2025 |
| Feb 14, 2025 | Christine Bellon Chief Legal Officer | MOption exercise Common Stock10b5-1 | +508 | $7.22 | $3,668 | 112,968 | Feb 19, 2025 |
| Feb 14, 2025 | Christine Bellon Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -10,000 | $34.00 | $340k | 102,968 | Feb 19, 2025 |
| Feb 14, 2025 | Christine Bellon Chief Legal Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,492 | $0.00 | $0 | 0 | Feb 19, 2025 |
| Feb 14, 2025 | Christine Bellon Chief Legal Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -508 | $0.00 | $0 | 10,410 | Feb 19, 2025 |
| Jan 31, 2025 | Amy Simon Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Feb 3, 2025 |
| Jan 30, 2025 | John M. Evans CEO | SOpen-market sale Common Stock10b5-1 | -29,800 | $26.75 | $797k | 908,859 | Feb 3, 2025 |
| Jan 31, 2025 | Giuseppe Ciaramella President | AGrant or award Stock Option (Right to Buy)derivative | +70,000 | $0.00 | $0 | 70,000 | Feb 3, 2025 |
| Jan 31, 2025 | Bethany J Cavanagh SVP, Finance and Treasurer | AGrant or award Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Feb 3, 2025 |
| Jan 31, 2025 | Christine Bellon Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Feb 3, 2025 |
| Jan 30, 2025 | John M. Evans CEO | SOpen-market sale Common Stock10b5-1 | -200 | $27.28 | $5,456 | 908,659 | Feb 3, 2025 |
| Jan 31, 2025 | John M. Evans CEO | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +155,000 | $0.00 | $0 | 155,000 | Feb 3, 2025 |
| Jan 2, 2025 | Bethany J Cavanagh SVP, Finance and Treasurer | SOpen-market sale Common Stock10b5-1 | -1,117 | $24.68 | $28k | 43,814 | Jan 6, 2025 |
| Jan 2, 2025 | Christine Bellon Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -1,241 | $24.68 | $31k | 102,968 | Jan 6, 2025 |
| Dec 31, 2024 | Sravan Kumar Emany Chief Financial Officer | AGrant or award Common Stock | +80,000 | $0.00 | $0 | 80,000 | Jan 2, 2025 |
| Dec 31, 2024 | Sravan Kumar Emany Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +160,000 | $0.00 | $0 | 160,000 | Jan 2, 2025 |
| Dec 17, 2024 | Giuseppe Ciaramella President | MOption exercise Common Stock | +53,500 | $0.67 | $36k | 162,650 | Dec 19, 2024 |
| Dec 17, 2024 | Giuseppe Ciaramella President | MOption exercise Stock Option (Right to Buy)derivative | -53,500 | $0.00 | $0 | 6,505 | Dec 19, 2024 |
| Dec 2, 2024 | Chirfi Guindo director | AGrant or award Stock Option (Right to Buy)derivative | +39,086 | $0.00 | $0 | 39,086 | Dec 4, 2024 |
| Nov 6, 2024 | Giuseppe Ciaramella President | SOpen-market sale Common Stock10b5-1 | -51,110 | $26.36 | $1.3M | 109,150 | Nov 8, 2024 |
| Oct 14, 2024 | Giuseppe Ciaramella President | MOption exercise Common Stock10b5-1 | +27,318 | $0.67 | $18k | 196,934 | Oct 16, 2024 |
| Oct 14, 2024 | Giuseppe Ciaramella President | MOption exercise Common Stock10b5-1 | +12,979 | $4.22 | $55k | 209,913 | Oct 16, 2024 |
| Oct 14, 2024 | Giuseppe Ciaramella President | MOption exercise Common Stock10b5-1 | +1,457 | $7.22 | $11k | 211,370 | Oct 16, 2024 |
| Oct 14, 2024 | Giuseppe Ciaramella President | SOpen-market sale Common Stock10b5-1 | -51,110 | $26.27 | $1.3M | 160,260 | Oct 16, 2024 |
| Oct 14, 2024 | Giuseppe Ciaramella President | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -27,318 | $0.00 | $0 | 0 | Oct 16, 2024 |
| Oct 14, 2024 | Giuseppe Ciaramella President | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,979 | $0.00 | $0 | 0 | Oct 16, 2024 |
| Oct 14, 2024 | Giuseppe Ciaramella President | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,457 | $0.00 | $0 | 0 | Oct 16, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Christine BellonChief Legal Officer
- Graham K Cooperdirector
- Bethany J CavanaghSVP, Finance and Treasurer
- Giuseppe CiaramellaPresident
- Sravan Kumar EmanyChief Financial Officer
- John M. EvansCEO
- Fmr LLCowner, other
- Mark Fishmandirector
- Chirfi Guindodirector, officer
- Carole Hoofficer, director
- John Maraganoredirector
- Christi Shawdirector
- Amy SimonChief Medical Officer
- Kathleen E Walshdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.